Tallac Therapeutics
Emma S. has over 18 years of work experience in the biopharmaceutical industry. Emma started their career as a Research Associate at Chiron Corporation in 2002, where they worked until 2005. Emma then joined Novartis Institutes for BioMedical Research as a Scientific Associate and remained there until 2012. In 2012, Emma joined Pfizer as a Senior Associate Scientist and worked there until 2015. Emma then joined Alexo Therapeutics, where they held the role of Scientist from 2015 until 2017, and then transitioned to the role of Senior Scientist, which they held until 2020. Currently, Emma is working as a Senior Scientist at Tallac Therapeutics.
Emma S. attended the University of California, Berkeley, but the specific start and end years, as well as the degree and field of study, are unknown.
Tallac Therapeutics
Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac’s pipeline of immunotherapy candidates are derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and preclinical development.